Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBIT (2016 - 2025)

Historic EBIT for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$22.5 million.

  • Seres Therapeutics' EBIT rose 2294.48% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.4 million, marking a year-over-year increase of 2013.39%. This contributed to the annual value of -$121.3 million for FY2024, which is 3781.81% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' EBIT is -$22.5 million, which was up 2294.48% from -$24.9 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year EBIT high stood at $68.4 million for Q3 2021, and its period low was -$70.6 million during Q1 2023.
  • Its 5-year average for EBIT is -$28.6 million, with a median of -$34.4 million in 2024.
  • Its EBIT has fluctuated over the past 5 years, first surged by 32806.13% in 2021, then crashed by 203887.93% in 2023.
  • Seres Therapeutics' EBIT (Quarter) stood at -$49.4 million in 2021, then soared by 96.5% to -$1.7 million in 2022, then crashed by 2038.88% to -$37.0 million in 2023, then increased by 22.12% to -$28.8 million in 2024, then grew by 22.05% to -$22.5 million in 2025.
  • Its EBIT was -$22.5 million in Q3 2025, compared to -$24.9 million in Q2 2025 and -$27.2 million in Q1 2025.